Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731610 | 1.00 | HPGDS (0.41) | HPGDSGPR119PRMT5CYP2C9CHEK2 | |
| SCHEMBL2732410 | 0.89 | HPGDS (0.42) | HPGDSPRMT5CHEK2USP30 | |
| SCHEMBL2732920 | 0.89 | HPGDS (0.42) | HPGDSPRMT5CHEK2USP30 | |
| SCHEMBL2731489 | 0.80 | USP30 (0.42) | HPGDSGPR119PRMT5CYP2C9USP30 | |
| SCHEMBL15248165 | 0.80 | HPGDS (0.42) | HPGDSGPR119PRMT5CYP2C9CHEK2 | |
| SCHEMBL15248281 | 0.79 | SCN9A (0.43) | HPGDSPRMT5CHEK2USP30 | |
| SCHEMBL2731625 | 0.74 | HPGDS (0.46) | HPGDSPRMT5CHEK2USP30 | |
| SCHEMBL2731621 | 0.74 | HPGDS (0.46) | HPGDSPRMT5CHEK2USP30 | |
| SCHEMBL15239513 | 0.73 | HPGDS (0.44) | HPGDSGPR119PRMT5CHEK2USP30 | |
| SCHEMBL15239511 | 0.73 | HPGDS (0.44) | HPGDSGPR119PRMT5CHEK2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8999966-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP | 2013-09-12 | — | — | US | disclosed |
| EP-2632268-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237518-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | HPGDS 1104/4885GPR119 1125/4885PRMT5 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.